Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 4—April 2019
Research

Pneumonia-Specific Escherichia coli with Distinct Phylogenetic and Virulence Profiles, France, 2012–2014

Béatrice La Combe, Olivier Clermont, Jonathan Messika, Matthieu Eveillard, Achille Kouatchet, Sigismond Lasocki, Stéphane Corvec, Karim Lakhal, Typhaine Billard-Pomares, Romain Fernandes, Laurence Armand-Lefevre, Sandra Bourdon, Jean Reignier, Vincent Fihman, Nicolas de Prost, Julien Bador, Julien Goret, Frederic Wallet, Erick Denamur, Jean-Damien RicardComments to Author , on behalf of the COLOCOLI group
Author affiliations: Infection, Antimicrobiens, Modélisation, Évolution, Paris, France (B. La Combe, O. Clermont, J. Messika, T. Billard-Pomares, R. Fernandes, L. Armand-Lefevre, E. Denamur, J.-D. Ricard); Université Paris Diderot, Paris (B. La Combe, O. Clermont, J. Messika, T. Billard-Pomares, R. Fernandes, L. Armand-Lefevre, E. Denamur, J.-D. Ricard); Hôpital Louis Mourier, Colombes, France (B. La Combe, J. Messika, T. Billard-Pomares, R. Fernandes, J.-D. Ricard); Centre Hospitalier Universitaire, Angers, France (M. Eveillard, A. Kouatchet, S. Lasocki); Centre Hospitalier Universitaire, Nantes, France (S. Corvec, J. Reignier); Hôpital Laënnec, Nantes (K. Lakhal); Hôpital Bichat, AP-HP, Paris (L. Armand-Lefevre, E. Denamur); Centre Hospitalier Départemental Vendée, La Roche-sur-Yon, France (S. Bourdon); Hôpital Henri Mondor, AP-HP, Créteil, France (V. Fihman, N. de Prost); Centre Hospitalier Universitaire Bocage Central, Dijon, France (J. Bador); Centre Hospitalier Universitaire Pellegrin, Bordeaux, France (J. Goret); Centre Hospitalier Régional Universitaire, Lille, France (F. Wallet)

Main Article

Table 2

Resistance and virulence traits of the 260 Escherichia coli isolates responsible for pneumonia in patients receiving mechanical ventilation, according to phylogenetic group, France, 2012–2014*

Trait Phylogenetic group
 p value Phylogenetic group
B2, n = 155 Non-B2, n = 105 A, n = 22 B1, n = 26 C, n = 20 D, n = 25 F, n = 11
iroN
 130 (83.9)
 52 (49.5)
 <0.0001
 10 (45.4)
 13 (50)
 16 (80)
 6 (24)
 6 (54.5)
sfa/foc
 109 (70.3)
 0
 <0.0001
 0
 0
 0
 0
 0
neuC
 41 (26.4)
 0
 <0.0001
 0
 0
 0
 0
 0
fyuA
 152 (98.1)
 51 (48.6)
 <0.0001
 7 (31.8)
 9 (34.6)
 16 (80)
 10 (40)
 8 (72.7)
hlyC
 98 (63.2)
 2 (1.9)
 <0.0001
 0
 2 (7.7)
 0
 0
 0
cnf1
 91 (58.7)
 1 (1)
 <0.0001
 0
 1 (3.8)
 0
 0
 0
aer
 65 (41.9)
 67 (63.8)
 0.0006
 14 (63.6)
 15 (57.7)
 14 (70)
 15 (60)
 8 (72.7)
papC
 100 (64.5)
 27 (25.7)
 <0.0001
 7 (31.8)
 3 (11.5)
 8 (40)
 8 (32)
 1 (9.1)
papGII
 27 (17.4)
 4 (3.8)
 0.0007
 0
 0
 0
 4 (16)
 0
papGIII
 64 (41.3)
 0
 <0.0001
 0
 0
 0
 0
 0
traT 70 (45.2) 82 (78.1) <0.0001 15 (68.2) 20 (76.9) 17 (85) 20 (80) 9 (81.8)
Virulence score, median (IQR)† 7 (5–7) 3 (2–4) <0.0001 2.5 (2–4) 3 (1–4) 4 (3–5) 3 (2–3) 3 (2.5–3)
Antimicrobial resistance
Amoxicillin
 75 (48.4)
 83 (79)
 <0.0001
 19 (86.4)
 19 (73)
 16 (80)
 19 (76)
 10 (90.9)
Amoxicillin/clavulanic acid
 66 (42.6)
 68 (64.8)
 0.0006
 18 (81.8)
 13 (50)
 15 (75)
 14 (56)
 8 (72.7)
Piperacillin/tazobactam
 21 (13.5)
 27 (25.7)
 0.02
 6 (27.3)
 6 (23.1)
 7 (35)
 3 (12)
 5 (45.4)
Cefotaxime
 11 (7.1)
 17 (16.2)
 0.02
 4 (18.2)
 4 (15.4)
 2 (10)
 3 (12)
 4 (36.4)
Ceftazidime
 12 (7.7)
 17 (16.2)
 0.04
 4 (18.2)
 4 (15.4)
 2 (10)
 3 (12)
 4 (36.4)
Imipenem
 0
 1 (1)
 0.4
 0
 1 (3.8)
 0
 0
 0
Gentamicin
 4 (2.6)
 10 (9.5)
 0.02
 3 (13.6)
 1 (3.8)
 2 (10)
 1 (4)
 3 (27.3)
Amikacin
 3 (1.9)
 1 (1)
 0.6
 0
 0
 0
 0
 1 (9.1)
Ofloxacin
 15 (9.7)
 28 (26.7)
 0.0005
 7 (31.8)
 6 (23.1)
 6 (30)
 2 (8)
 6 (54.5)
Ciprofloxacin 13 (8.4) 24 (22.9) 0.002 7 (31.8) 5 (19.2) 6 (30) 2 (8) 4 (36.4)
Resistance score, median (IQR)‡ 1.5 (0–4) 4.5 (2.5–7) <0.0001 5 (3.5–8) 4 (1–6) 4.5 (3.5–7.5) 4 (1.5–5.5) 7.5 (5–9)
ESBL phenotype
 10 (6.4)
 12 (11.4)
 0.2
 4 (18.2)
 1 (3.8)
 1 (4)
 2 (8)
 3 (27.3)
WT phenotype 84 (54.2) 24 (22.9) <0.0001 4 (18.2) 7 (26.9) 6 (24) 7 (28) 1 (9.1)

*Values are no. (%) except as indicated. ESBL, extended-spectrum beta-lactamase; IQR, interquartile range; WT, wild type (susceptible to all tested antimicrobials).
†Virulence score was calculated, defined by the number of present virulence factors among the 11 tested.
‡Resistance score was defined as the sum of inactive in vitro antimicrobial agents for each isolate. Tested antimicrobials were gentamicin, amikacin, minocycline, nalidixic acid, ofloxacin, ciprofloxacin, fosfomycin, furans, trimethoprim, amoxicillin, amoxicillin-clavulanic acid, ticarcillin, piperacillin, piperacillin-tazobactam, imipenem, cefotaxime, and ceftazidime. A score of 1 was attributed for a resistant, 0.5 for an intermediary, and 0 for a sensitive isolate; a higher score thus indicated a more resistant isolate. For each antimicrobial, resistance is defined by the sum of resistant or intermediary isolates.

Main Article

1Group members are listed at the end of this article.

Page created: March 04, 2019
Page updated: March 04, 2019
Page reviewed: March 04, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external